Could This Cathie Wood Stock Soar in 2027?
Key PointsIntellia Therapeutics could earn its first regulatory approval next year.
Cathie Wood's Ark Invest has poured money into biotechs focused on gene-editing, a field with the potential to transform treatments for numerous diseases. Intellia Therapeutics (NASDAQ:NTLA), a company within this sector, appears to be on the verge of a significant breakthrough. Shares of Intellia have outperformed the broader market this year, with an important milestone looming in 2027.
Could the company sustain its current upward trajectory? Intellia specializes in developing gene-editing therapies for rare diseases with high unmet medical needs. Earlier this year, the company announced encouraging Phase 3 results for its leading candidate, lonvo-z, in patients suffering from hereditary angioedema (HAE). HAE causes painful and sometimes life-threatening episodes of swelling throughout the body.
While existing treatments are available for HAE, lonvo-z offers a promising alternative as it is a one-time therapy for the condition.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
